Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Zannad, F; Garcia, AA; Anker, SD; Armstrong, PW; Calvo, G; Cleland, JG; Cohn, JN; Dickstein, K; Domanski, MJ; Ekman, I; Filippatos, GS; Gheorghiade, M; Hernandez, AF; Jaarsma, T; Koglin, J; Konstam, M; Kupfer, S; Maggioni, AP; Mebazaa, A; Metra, M; Nowack, C; Pieske, B; Piña, IL; Pocock, SJ; Ponikowski, P; Rosano, G; Ruilope, LM; Ruschitzka, F; Severin, T; Solomon, S; Stein, K; Stockbridge, NL; Stough, WG; Swedberg, K; Tavazzi, L; Voors, AA; Wasserman, SM; Woehrle, H; Zalewski, A; McMurray, JJ.
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document.
Eur J Heart Fail. 2013; 15(10):1082-1094 Doi: 10.1093/eurjhf/hft095 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Pieske Burkert Mathias

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Endpoint selection is a critically important step in clinical trial design. It poses major challenges for investigators, regulators, and study sponsors, and it also has important clinical and practical implications for physicians and patients. Clinical outcomes of interest in heart failure trials include all-cause mortality, cause-specific mortality, relevant non-fatal morbidity (e.g., all-cause and cause-specific hospitalization), composites capturing both morbidity and mortality, safety, symptoms, functional capacity, and patient-reported outcomes. Each of these endpoints has strengths and weaknesses that create controversies regarding which is most appropriate in terms of clinical importance, sensitivity, reliability, and consistency. Not surprisingly, a lack of consensus exists within the scientific community regarding the optimal endpoint(s) for both acute and chronic heart failure trials. In an effort to address these issues, the Heart Failure Association of the European Society of Cardiology (HFA-ESC) convened a group of expert heart failure clinical investigators, biostatisticians, regulators, and pharmaceutical industry scientists (Nice, France, 12-13 February 2012) to evaluate the challenges of defining heart failure endpoints in clinical trials and to develop a consensus framework. This report summarizes the group's recommendations for achieving common views on heart failure endpoints in clinical trials.
Find related publications in this database (using NLM MeSH Indexing)
Clinical Trials as Topic - standards
Heart Failure - mortality
Hospitalization -
Humans -
Outcome Assessment (Health Care) - standards
Recurrence -

Find related publications in this database (Keywords)
Heart failure
Clinical trials
© Med Uni Graz Impressum